UNDERSTANDING SLEEP, RECOVERY & PEPTIDE RESEARCH

Understanding Sleep and Recovery

Normal sleep occurs in repeating cycles that include non-rapid eye movement (NREM) and rapid eye movement (REM) sleep. During sleep, the body continues numerous physiological processes involving:

• Hormonal regulation
• Immune function
• Metabolic regulation
• Memory and neurological function
• Cellular maintenance
• Musculoskeletal recovery

Sleep architecture, duration, and quality can be affected by age, health conditions, medications, stress, lifestyle, environmental factors, and sleep disorders. Sleep is important to normal recovery, but the relationship between sleep stages, hormones, and tissue repair is complex.

DSIP / Emideltide

Delta sleep-inducing peptide, commonly abbreviated DSIP and also referred to as emideltide, is a peptide that has been investigated experimentally in relation to sleep.

Older human studies evaluated DSIP using measures such as sleep latency, sleep efficiency, sleep stages, and subjective sleep quality. Results have been inconsistent.

One small double-blind study involving patients with chronic insomnia reported changes in certain objective sleep measurements but concluded that short-term DSIP treatment was unlikely to provide major therapeutic benefit (PubMed). The available human evidence is limited, and DSIP has not been established as a treatment for insomnia or other sleep disorders.

DSIP is not an FDA-approved treatment for sleep disorders.

BPC-157

BPC-157 is a synthetic peptide that has been investigated experimentally in relation to tissue repair and other biological processes. Research has primarily involved laboratory and animal models examining tissue healing, inflammatory processes, blood-vessel formation, tendon and ligament injury, skeletal muscle injury, and gastrointestinal tissue.

Human clinical evidence remains very limited. Current evidence does not establish BPC-157 as an FDA-approved treatment for sleep enhancement, recovery, or tissue repair in humans.

FDA has stated that it has identified no or only limited safety information for proposed routes of administration of compounded BPC-157.

CJC-1295

CJC-1295 is a synthetic peptide related to growth hormone-releasing hormone (GHRH). It has been investigated for its effects on growth hormone and insulin-like growth factor-1 (IGF-1) physiology.

Growth hormone secretion normally varies throughout the day and is influenced by several physiological factors, including sleep. However, the biological relationship between sleep and growth hormone should not be interpreted as evidence that CJC-1295 improves sleep or produces tissue repair.

Available human clinical information involving CJC-1295 is limited. CJC-1295 is not an FDA-approved medication.

FDA has identified limited clinical data and reported serious adverse events associated with CJC-1295, including increased heart rate and systemic vasodilatory reaction.

Understanding the Evidence

The evidence supporting DSIP, BPC-157, and CJC-1295 differs by substance. Some research involves laboratory or animal models, while limited human studies exist for certain substances. It is important to distinguish among biological mechanisms, laboratory research, animal studies, small human studies, controlled clinical trials, and FDA-approved medical treatments.

A biological mechanism or positive result in an animal study does not establish that a substance is safe or effective in humans. Additional controlled human research is needed to determine safety, effectiveness, appropriate dosing, potential interactions, and long-term risks.

Sleep Problems Should Be Evaluated

Persistent difficulty sleeping can have many potential causes, including insomnia, sleep apnea, circadian rhythm disorders, medications, mental health conditions, pain, hormonal or metabolic conditions, alcohol or other substances, and environmental and behavioral factors.

Identifying the underlying cause of a sleep problem can be an important part of determining appropriate medical care. Established approaches to improving sleep may include behavioral interventions, treatment of underlying medical conditions, changes in sleep habits, and FDA-approved medications when clinically appropriate.

Regulatory and Safety Considerations

DSIP (emideltide), BPC-157, and CJC-1295 are not FDA-approved treatments for improving sleep or promoting tissue recovery.

FDA currently identifies all three among bulk drug substances for which the agency has identified potential significant safety risks in the context of compounding. FDA reports that available safety information for emideltide and BPC-157 is limited or absent for proposed routes of administration. For CJC-1295, available clinical data are limited and FDA has identified reports of serious adverse events.

Compounded medications are not FDA-approved. FDA does not review compounded drugs for safety, effectiveness, or quality before they are marketed. The regulatory status of individual substances can change as additional evidence is reviewed.

Educational Disclaimer

This page is provided for general educational purposes only. It is not intended to provide medical advice, diagnosis, or treatment. References to peptides, hormones, biological mechanisms, laboratory research, animal studies, or areas of clinical investigation are provided for educational purposes and should not be interpreted as a recommendation or endorsement of a particular substance or treatment. Discussion of an investigational substance does not establish that the substance is safe, effective, FDA-approved, or appropriate for medical use. Treatment decisions should be individualized and made with an appropriately licensed healthcare professional.